Medical / Pharmaceuticals
Releases published in the last 30 days. 
Page 1 of 3
- Heartseed Announces First Patient Dosed in a Phase I/II EMERALD Study with HS-005 – a Cell Therapy Administered via Catheter, Designed to Restore Heart Function in People with Severe Heart Failure
- 6/15/2026 12:16:05 PM
- Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation (Nikon), manufactures iPSC-derived purified cardiomyocyte spheroids of HS-005, under contract to Heartseed Inc.(Heartseed).
- CONV2X Announces Smart Technology Transformation in Healthcare & Life Sciences Summit in New York City
- 6/15/2026 10:56:45 AM
- CONV2X Smart Technology Transformation in Healthcare & Life Sciences, announced its annual two-day executive summit taking place October 29–30, 2026 at the Historic GE Building, ILR Conference Center, 570 Lexington Avenue, New York, NY.
- Elsevier launches Ebola Information Center with free clinical and research resources to support response to outbreak
- 6/15/2026 10:54:14 AM
- Following the World Health Organization’s declaration of an Ebola outbreak caused by Bundibugyo virus in the Democratic Republic of Congo and Uganda as a Public Health Emergency of International Concern (PHEIC), Elsevier, a global leader in scientific information and analytics, has launched its Ebola Information Center to provide healthcare professionals, researchers, …
- Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
- 6/15/2026 10:48:37 AM
- Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks If approved, Ultomiris would be the first C5 complement inhibitor available for this rare kidney disease Alexion, AstraZeneca Rare Disease’s supplemental Biologics License Application (sBLA) for …
- Caring for non-communicable diseases during pregnancy, expert convening
- 6/15/2026 10:36:28 AM
- The World Health Organization (WHO) is developing new recommendations to improve care for pregnant and postpartum women living with noncommunicable diseases (NCDs).
- “Beyond Feet on Fire” is Free to Download for Only Five Days (Until 6/19/26)
- 6/15/2026 6:00:00 AM
- Best Seller Publishing announces the release of Dr. Paul Fisher’s new book, “Beyond Feet on Fire: How To Reverse Neuropathy Without Drugs and Surgery.” It will be available in the Amazon store for free for only five days.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- 6/12/2026 10:38:47 AM
- • Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. • Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 • Over half a million eyes worldwide …
- Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
- 6/10/2026 6:17:01 PM
- Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.
- Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - May 2026
- 6/10/2026 9:20:39 AM
- At the mid-way point of Immunization Agenda 2030 (IA2030), countries gathering at the Seventy-ninth World Health Assembly (WHA79) marked an important moment in reaffirming their commitment to reaching everyone, everywhere with life-saving vaccines.
- AMA adopts new policies to improve affordable access to obesity treatments
- 6/9/2026 9:02:36 AM
- Physicians and medical students convened for the Annual Meeting of the American Medical Association’s (AMA) House of Delegates today and adopted new policies aimed at improving patient access to evidence-based obesity treatments while advancing broader efforts to address prescription drug affordability and insurance coverage barriers.
- 3D-printed devices could streamline the production of drug-delivery microparticles
- 6/9/2026 8:39:59 AM
- MIT researchers have demonstrated a low-cost design of specialized electronic nozzles, called triaxial electrospray emitters, that could be used to manufacture time-release drug-delivery particles or self-healing materials efficiently and at scale.
- Wiley Launches Advanced Brain to Push Disciplinary Boundaries Across Neuroscience & Related Fields
- 6/9/2026 8:08:00 AM
- Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence, today announced the launch of Advanced Brain, an open access, interdisciplinary journal dedicated to publishing cutting-edge research across neuroscience, neurology, psychiatry and psychology.
- Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
- 6/8/2026 10:37:39 AM
- Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector • Sarclisa administered via the CirCLIQ ® OBI offers a treatment experience designed around the needs of patients and HCPs and enables flexible administration in either home or outpatient settings • Sarclisa is the first anticancer treatment to …
- Thrifty Food Plan Costs Vary Widely Across US Regions and Cities
- 6/8/2026 9:58:55 AM
- A recent study in the Journal of Nutrition Education and Behavior (JNEB), published by Elsevier, examined how the cost of the USDA’s Thrifty Food Plan (TFP), which serves as the basis for determining maximum SNAP benefits, varied across geographic regions, metropolitan areas, and seasons from 2012 to 2018.
- Can taking aspirin uncover asymptomatic bladder cancer?
- 6/5/2026 9:21:01 AM
- The presence of blood cells in urine is a sign of bladder cancer. Because aspirin blocks platelets from forming harmful blood clots, the medication can cause mild bleeding or worsen existing bleeding in the urinary tract.
- GEODIS to enhance its pharmaceutical logistics capabilities and move into a new temperature controlled, GDP compliant warehouse in Manchester
- 6/4/2026 10:28:06 AM
- GEODIS, a world leader in transport and logistics, announces the opening of a temperature-controlled GDP-compliant pharmaceutical warehouse close to the airport in Manchester designed to support both inventory management and cross-docking operations, reinforcing its capabilities in the fast-growing Pharma & Healthcare sector in the UK and Ireland.
- Sanofi launches 2026 global employee stock purchase plan
- 6/4/2026 10:25:32 AM
- Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results.
- Kaiser Permanente names Emily Holliman president of Mid-Atlantic States region
- 6/3/2026 10:07:22 AM
- Kaiser Permanente has appointed Emily Holliman as president of Kaiser Permanente in the Mid-Atlantic States, effective immediately. Holliman has served as the region’s interim president since June 2025, leading efforts to provide high-quality, integrated health care and coverage to the organization’s 750,551 members across 35 medical centers in Maryland, Virginia, and …
- Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
- 6/3/2026 10:03:16 AM
- · Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function · Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued …
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
- 6/2/2026 10:54:17 AM
- The U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge.